Patents by Inventor Cristian-George Bologa

Cristian-George Bologa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human GLUT5 specific inhibitors and methods of treatment
    Patent number: 10822325
    Abstract: The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human GLUT5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of GLUT5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through GLUT5, including such disease states and conditions as GLUT5 deficiency syndrome, diabetes (type I and II), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: November 3, 2020
    Inventors: Tudor I. Oprea, Cristian George Bologa, Oleg Ursu, Jun-Yong Choe, Cristina Iancu
  • HUMAN GLUT5 SPECIFIC INHIBITORS AND METHODS OF TREATMENT
    Publication number: 20180170897
    Abstract: The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human GLUT5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of GLUT5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through GLUT5, including such disease states and conditions as GLUT5 deficiency syndrome, diabetes (type I and II), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 21, 2018
    Inventors: Tudor I. Oprea, Cristian George Bologa, Oleg Ursu, Jun-Yong Choe, Cristina Iancu
  • Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
    Patent number: 8487100
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: July 16, 2013
    Assignee: STC.UNM
    Inventors: Eric R Prossnitz, Sergey E Tkatchenko, Chetana M Revankar, Larry A Sklar, Jeffrey B Arterburn, Daniel F Cimino, Tudor I Oprea, Cristian-George Bologa, Bruce S Edwards, Alexandor Kiselyov, Susan M Young
  • COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF
    Publication number: 20110092533
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.
    Type: Application
    Filed: December 14, 2010
    Publication date: April 21, 2011
    Applicant: STC. UNM
    Inventors: Eric R. PROSSNITZ, Sergey E. Tkatchenko, Chetana M. Revankar, Larry A. Sklar, Jeffrey B. Arterburn, Daniel F. Cimino, Tudor I. Oprea, Cristian-George Bologa, Bruce S. Edwards, Alexander Kiselyov, Susan M. Young
  • Compounds for binding to ER?/? and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
    Patent number: 7875721
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: January 25, 2011
    Assignee: STC.UNM
    Inventors: Eric R. Prossnitz, Sergey E. Tkatchenko, Chetana M. Revankar, Larry A. Sklar, Jeffrey B. Arterburn, Daniel F. Cimino, Tudor I. Oprea, Cristian-George Bologa, Bruce S. Edwards, Alexander Kiselyov, Susan M. Young
  • Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
    Publication number: 20080167334
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.
    Type: Application
    Filed: August 2, 2006
    Publication date: July 10, 2008
    Inventors: Eric R. Prossnitz, Sergey E. Tkatchenko, Chetana M. Revankar, Larry A. Sklar, Jeffrey B. Arterburn, Daniel F. Cimino, Tudor I. Oprea, Cristian-George Bologa, Bruce S. Edwards, Alexander Kiselyov, Susan M. Young